Prostate Cancer Clinical Trials in Baltimore

Showing 81-100 of 228 trials

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

NCT02420977

This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.

Advanced Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins23 participantsStarted Dec 2018

Baltimore, Maryland, United States

ACTIVE_NOT_RECRUITINGPHASE2< 1 mile

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650

This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.

Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins150 participantsStarted Mar 2018

Baltimore, Maryland, United States

TERMINATEDPHASE2< 1 mile

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more

Seagen Inc.205 participantsStarted Oct 2019

Chandler, Arizona, United States • Los Angeles, California, United States • Santa Rosa, California, United States +63 more locations

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Prostate Cancer Trials in Other Cities

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

PK and Dose Escalation and Expansion Study of DST-2970

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Stockholm3 Validation Study in a Multi-Ethnic Cohort

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Other Conditions in Baltimore